



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Duff et al.

Atty. Docket No.: MSA-004.01

Serial No: 09/247,874

Filing Date: February 10, 1999

For: *Therapeutics and Diagnostics Based on a
Novel IL-1B Mutation*

ATTN: Box Missing Parts
Assistant Commissioner for Patents
U.S. Patent and Trademark Office
Washington, D.C. 20231

Certificate of First Class Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

April 16, 1999

By Carmen Parra

Date of Signature
and of Mail Deposit

Carmen Parra

FEE TRANSMITTAL AND RESPONSE TO NOTICE TO FILE MISSING PARTS

Dear Sir/Madam:

Responsive to the Notice to File Missing Parts of Application dated February 25, 1999, Applicants' attorney submits herewith one executed Declaration, Petition and Power of Attorney, one executed Verified Statement Claiming Small Entity Status, and a check in the amount of **\$890.00** to cover the cost of the filing fee (\$825.00) and surcharge/small entity (\$65.00). A copy of Form PTO-1533 is also enclosed.

Responsive to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, Applicants' attorney submits herewith Sequence Listing and Diskette and Statement to Support Filing and Submission in Accordance with 37 C.F.R. §§1.821-1.825.

The filing fee has been calculated as shown below:

	# FILED	# EXTRA	SMALL ENTITY	OTHER THAN SMALL ENTITY
BASIC FEE			Rate	Fee
TOTAL CLAIMS	42 - 20 =	22*	\$380	380.00
INDEP. CLAIMS	6 - 3 =	3*	x \$9	198.00
[X] MULTIPLE DEP.	CLAIMS PRESENTED		x \$39	117.00
			\$130	130.00
			TOTAL:	825.00

[X] A check in the amount of \$890.00 to cover the filing fee (\$825.00) and surcharge (\$65.00) is enclosed.

[X] Please charge any additional fees or credit any overpayments associated with this communication to our Deposit Account No. **06-1448**. A duplicate copy of this sheet is enclosed.


Respectfully submitted,
FOLEY, HOAG & ELIOT LLP



Beth E. Arnold
Registration No. 35,430
Attorney for Applicants

Date: April 16, 1999

Patent Group
FOLEY, HOAG & ELIOT LLP
One Post Office Square
Boston, MA 02109
(617) 832-1000



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARK
Washington, D.C. 20231

APPLICATION NUMBER	FILED/RECEIVED DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO./TITLE
09/247,874	02/10/99	DUFF	G MSA-004.01

09/247,874 02/10/99 DUFF

G MSA-004.01

0242/0225

NOT ASSIGNED

PATENT GROUP

FOLEY HOAG & ELIOT
ONE POST OFFICE SQUARE
BOSTON MA 02109-2170

4/25/99

1643

DATE MAILED:

02/25/99

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

- 1. This application fails to comply with the requirements of 37 CFR 1.821 - 1.825.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- 7. OTHER: _____

APPLICANT MUST PROVIDE:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing."
- An initial or substitute paper copy of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CONTACT:

- For Rules Interpretation, call (703) 308-1123.
- For CRF submission help, call (703) 308-4212.
- For PatentIn software help, call (703) 308-6856.

D. Bell
Customer Service Center

Initial Patent Examination Division (703) 308-1202